List of Seglentis drug patents

Seglentis is owned by Kowa Pharms.

Seglentis contains Celecoxib; Tramadol Hydrochloride.

Seglentis has a total of 7 drug patents out of which 0 drug patents have expired.

Seglentis was authorised for market use on 15 October, 2021.

Seglentis is available in tablet;oral dosage forms.

Seglentis can be used as a method for treatment of pain in adults using tramadol hydrochloride and celecoxib.

The generics of Seglentis are possible to be released after 03 June, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9012440 KOWA PHARMS Co-crystals of tramadol and coxibs
Apr, 2030

(7 years from now)

US10238668 KOWA PHARMS Co-crystals of tramadol and coxibis
Apr, 2030

(7 years from now)

US8598152 KOWA PHARMS Co-crystals of tramadol and coxibs
Apr, 2030

(7 years from now)

US10245276 KOWA PHARMS Co-crystals of tramadol and coxibs
Apr, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11478488 KOWA PHARMS NA
Apr, 2030

(7 years from now)

US10548909 KOWA PHARMS Co-crystals of tramadol and coxibs
Apr, 2030

(7 years from now)

US8846744 KOWA PHARMS Pharmaceutical compositions of co-crystals of tramadol and coxibs
Jun, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Oct 15, 2024

Drugs and Companies using CELECOXIB; TRAMADOL HYDROCHLORIDE ingredient

Market Authorisation Date: 15 October, 2021

Treatment: A method for treatment of pain in adults using tramadol hydrochloride and celecoxib

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in